Characterization Of The Flux Performance Of Nanoformed And Untreated Crystalline Piroxicam Solid Suspensions, And The Relative Contributions Of The Particle Drifting Effect To In Vitro Flux

Pion and Nanoform presented the following poster at the Controlled Release Society Annual Meeting & Expo 2023. The poster demonstrates the application of in vitro flux assays to nanoparticles, with data on how the in vitro permeability apparatus can be utilized to characterize the membrane flux performance of an API formulated as a nanosuspension. Using piroxicam (PRX), a non-steroidal anti-inflammatory drug, as an example, it was demonstrated that by using PRX nanosuspension produced using Nanoform’s CESS^® technology with a better flux performance compared with an unprocessed PRX solid suspension.